Most Accessed Articles

P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

, 2013; 13(3): 326-346.

Ziyad Binkhathlan and Afsaneh Lavasanifar


DOI: 10.2174/15680096113139990076


Multimodal HDAC Inhibitors with Improved Anticancer Activity

, 2018; 18(1): 39-56.

Rainer Schobert and Bernhard Biersack*


DOI: 10.2174/1568009617666170206102613


Potential Anti-cancer Drugs Commonly Used for Other Indications

, 2015; 15(1): 35-52.

Veronika Hanusova, Lenka Skalova, Vera Kralova and Petra Matouskova


DOI: 10.2174/1568009615666141229152812


Lung Cancer Stem Cells: An Epigenetic Perspective

, 2018; 18(1): 16-31.

Samriddhi Shukla, Sajid Khan, Sonam Sinha and Syed Musthapa Meeran*


DOI: 10.2174/1568009617666170206104623


Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer

, 2018; 18(4): 306-327.

Heena Singla, Anjana Munshi*, Raja Paramjit Singh Banipal and Vinod Kumar*


DOI: 10.2174/1568009617666170623122213


Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation

, 2003; 3(1): 1-19.

R. Z. Yusuf, Z. Duan, D. E. Lamendola, R. T. Penson and M. V. Seiden


DOI: 10.2174/1568009033333754


A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

, 2015; 15(8): 665-683.

Otília Menyhart, Libero Santarpia and Balazs Gyorffy


DOI: 10.2174/156800961508151001101742


The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations

, 2018; 18(4): 355-364.

Dearbhaile C. Collins, Maxime Chenard-Poirier and Juanita S. Lopez*


DOI: 10.2174/1568009617666170927114440


Transforming Cancer Epigenetics Using Nutritive Approaches and Noncoding RNAs

, 2018; 18(1): 32-38.

Centdrika R. Dates and Trygve O. Tollefsbol*


DOI: 10.2174/1568009617666170203165326


Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science